Research programme: microbiome-based therapeutics - MicrobioticaAlternative Names: bacteriotherapies - Microbiotica
Latest Information Update: 05 Jan 2017
At a glance
- Originator Wellcome Trust Sanger Institute
- Developer Microbiotica; Wellcome Trust Sanger Institute
- Class Bacteria
- Mechanism of Action Bacteria replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified